View Older Stories View More Recent Stories
-
RBC Capital on argenx SE (ARGX): 'We Would Remain Buyers'
-
argenx SE (ARGX) PT Raised to $882 at Stifel
-
Oppenheimer Reiterates Outperform Rating on argenx SE (ARGX)
-
Truist Securities Reiterates Buy Rating on argenx SE (ARGX)
-
Truist Securities Assumes argenx SE (ARGX) at Buy
-
Deutsche Bank Downgrades argenx SE (ARGX:BB) (ARGX) to Hold
-
BofA Securities on argenx SE (ARGX): 'We see multiple shots on goal to expand the commercial opportunity with multiple phase 3 readouts for Vyvgart'
-
argenx SE (ARGX) PT Raised at Piper Sandler Following Successful Seronegative gMG Readout
-
JPMorgan Reiterates Overweight Rating on argenx SE (ARGX:BB) (ARGX)
-
argenx SE (ARGX) PT Raised to $808 at Jefferies
-
Oppenheimer Reiterates Outperform Rating on argenx SE (ARGX)
-
RBC on argenx SE (ARGX): 'Vyvgart Hits in snMG, TAM Likely to Be Expanded by an Additional 11k Patients'
-
RBC Capital Starts argenx SE (ARGX) at Outperform
-
argenx SE (ARGX:BB) (ARGX) PT Raised to EUR655 at Deutsche Bank
-
argenx SE (ARGX) PT Raised to $1,070 at Guggenheim
-
argenx SE (ARGX) PT Raised to $796 at Scotiabank
-
argenx SE (ARGX) PT Raised to $774 at H.C. Wainwright
-
argenx SE (ARGX) PT Raised to $778 at Oppenheimer
-
argenx SE (ARGX) PT Raised to $880 at BofA Securities
-
argenx (ARGX) Reports Q2 EPS of $6.32
-
argenx (ARGX) Added to BofA US 1 List
-
15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings
-
argenx SE (ARGX) PT Raised to $829 at BofA Securities
-
Morgan Stanley Assumes argenx SE (ARGX) at Overweight
-
H.C. Wainwright Reiterates Buy Rating on argenx SE (ARGX)
-
Citi on argenx SE (ARGX): 'We remain Buyers on today’s weakness'
-
argenx (ARGX) Weakness Said to be Tied to Negative FDA Report
-
TD Cowen on argenx SE (ARGX): 'Sjogren's Shows Multi-Billion Potential'
-
H.C. Wainwright Reiterates Buy Rating on argenx SE (ARGX)
-
argenx (ARGX) Added to Wedbush Best Ideas List
-
Recent pullback offers an attractive buying opportunity in this stock: Citi
-
argenx SE (ARGX) PT Lowered to $699 at Citizens JMP
-
Baird Upgrades argenx SE (ARGX) to Outperform
-
argenx SE (ARGX:BB) (ARGX) PT Lowered to EUR525 at Deutsche Bank
-
TD Cowen on argenx SE (ARGX): 'We View the Selloff as a Buying Opportunity'
-
Leerink Partners on argenx SE (ARGX): 'Share Pullback Creates Buying Opp'ty'
-
argenx (ARGX) Tops Q1 EPS by 34c
-
TD Cowen Reiterates Buy Rating on argenx SE (ARGX)
-
Piper Sandler: 'What Biotech Names to Own in Market Volatility'
-
Stifel Reiterates Buy Rating on argenx SE (ARGX)
-
H.C. Wainwright Reiterates Buy Rating on argenx SE (ARGX)
-
Guggenheim Reiterates Buy Rating on argenx SE (ARGX)
-
argenx (ARGX) announces FDA approval of VYVGART Hytrulo
-
Bernstein SocGen Group Double Upgrades argenx SE (ARGX:BB) (ARGX) to Outperform
-
TD Cowen Names argenx SE (ARGX) 'Europe Best Ideas'
-
Deutsche Bank Upgrades argenx SE (ARGX:BB) (ARGX) to Hold
-
argenx SE (ARGX) PT Raised to $1,100 at Guggenheim
-
argenx SE (ARGX) PT Raised to $720 at H.C. Wainwright
-
argenx SE (ARGX) PT Raised to $701 at Citizens JMP
-
argenx SE (ARGX) PT Raised to $761 at TD Cowen

